Proteins and Assays Core for Cancer Research (APOBEC3 enzymes)
Official title: CORE B – PROTEINS & ASSAYS
Funded at University of Texas Hlth Science Center · NIH-11418449 · Data updated 2026-11-12
A funded core facility helps scientists study APOBEC3 enzymes that may drive mutations in many cancers by providing proteins, antibodies, and standardized assays.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 9, 2019 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $317,011 |
| NIH project number | 5P01CA234228-07 |
| Project ID | NIH-11418449 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancers known to harbor APOBEC3-related mutational signatures may benefit from future advances driven by this core’s tools and findings.
✕Less likely to help
Patients not directly involved in clinical studies; this core primarily supports laboratory research and tool development.
What this research studies
If you or a loved one is affected by cancer, this core supports researchers who study the APOBEC3 family of enzymes (A3A and A3B) that can influence cancer mutations. The core has already developed methods to produce active APOBEC3 proteins, create specific antibodies, and run assays that measure enzyme activity and binding. It will continue supplying essential proteins, antibodies, and standardized tests, and will develop new SOPs to make these tools more accessible to researchers and collaborators. This work aims to enable more accurate cancer research and help translate findings into better diagnostics and therapies.
Why it matters
Potential benefit: If successful, this core could accelerate cancer discoveries by providing reliable tools that reveal how APOBEC3 enzymes contribute to cancer progression and treatment response.
How similar studies have gone: Previous work with APOBEC3 enzymes has yielded functional tools and validated assays, supporting the potential for impactful follow-on research.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Carpenter, Michael Allen — University of Texas Hlth Science Center
- Study coordinator: Carpenter, Michael Allen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.